Hypothesis PaperHomocysteine and Alzheimer's disease: a modifiable risk?
Introduction
A recent article reported that elevated plasma homocysteine is a strong, independent risk factor for the development of Alzheimer's disease (AD) [1], but did not shed light on any relevant mechanism(s). Elevated plasma homocysteine implies impaired cellular clearance of homocysteine and elevated brain homocysteine has been reported in AD [2]. Furthermore, hydrogen sulfide (H2S), a neuromodulator, produced in response to neuronal excitation [3] is severely reduced in AD [2]. Both observations are explained by reduced activity of the enzyme cystathionine β-synthase (EC 4.2.1.22) (CβS), which is one of two available routes of neuronal homocysteine metabolism, and the source of H2S in brain.
Section snippets
General considerations
Homocysteine is a key metabolic intermediate in sulfur amino acid metabolism [4]. Briefly, homocysteine is remethylated to methionine by 5-methyltetrahydrofolate–homocysteine S-methyltransferase (EC 2.1.1.13), which is a 5-methyltetrahydrofolate- and vitamin B12-dependent pathway, and by betaine–homocysteine S-methyltransferase (EC 2.1.1.5), which is part of a mitochondrial choline-degrading pathway. The former is active in brain and the latter is not. Homocysteine is also catabolized via the
CβS function in brain
What is the function of CβS in brain? As stated above, CβS catalyzes the condensation reaction of homocysteine and l-serine, which forms cystathionine. We surmise that CβS takes on increased importance for homocysteine homeostasis in brain tissue when homocysteine methylation via methyltetrahydrofolate-homocysteine S-methyltransferase is impaired, in folate deficiency, for example. Efflux from neurons would reduce neuronal homocysteine but risks excitotoxicity [6]. By a different reaction
Hypothesis
We hypothesize that reduced CβS activity and elevated homocysteine (perhaps secondary to heme deficiency) may be part of a vicious circle, involving iron regulation and oxidative stress, which contributes to the early oxidative pathophysiology that is seen in AD brain. A model of AD progression, which emphasizes the primacy of these early metabolic changes in AD brain, is shown in Fig. 1.
Homocysteine mobilizes storage iron from ferritin in vitro [11]. Moreover, sulfhydryl compounds, like
Testing the hypothesis
Mutations in the CβS gene are relatively common and obligate heterozygotes can have significantly reduced CβS activity [4]. Moreover, a significant number of CβS heterozygotes may also be heterozygous for other AD-related genes. Thus, hemochromatosis is the most common inherited monogenic disease of people of European descent [21]. The HFE gene regulates iron homeostasis, and a mutation in the HFE gene was reported to affect the age of onset of sporadic AD [21]. In this regard it may be of
Conclusions
Elevated homocysteine may be part of a vicious circle involving iron regulation and oxidative stress that could account for a majority of the early events seen in AD. The early stage of AD may be a critical period in disease progression during which affected neurons undergo adaptive change and switch from a functional mode to a survival mode of existence [23]. It may also be the critical stage of AD as far as therapeutic intervention is concerned [23]. Our proposed model is consistent with the
Broader implications
Variations in the ferric cycle shown in Fig. 1 may be relevant in other diseases. Of particular interest, the CβS gene is localized on chromosome 21, the locus of several familial AD pedigrees as well as being trisomic in Down syndrome. In Down syndrome, both CβS gene dosage and CβS activity are increased [28]. In contrast to AD, increased generation of H2S in brain has been postulated as a mechanism of cognitive dysfunction in Down syndrome [29]. Also in contrast to AD, homocysteine is reduced
Acknowledgements
This work was supported by the Medical Research Service of the Department of Veterans Affairs (B.E.D.) and by the National Institutes of Health and the Alzheimer's Association (A.K.R., G.P., M.A.S.). None of the sponsors, however, had any direct involvement with this work. The authors also acknowledge Dr. Peter Sinclair (VAM&ROC, White River Junction, VT, and Dartmouth Medical School) and Dr. Glenn Gerhard (presently at the Weis Center for Research, Geisinger Clinic, Danville, PA) for many
References (33)
- et al.
Brain hydrogen sulfide is severely decreased in Alzheimer's disease
Biochem. Biophys. Res. Commun
(2002) - et al.
Reaction mechanism and regulation of cystathionine β-synthase
Biochim. Biophys. Acta
(2003) - et al.
An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript
J. Biol. Chem
(2002) - et al.
δ-Aminolevulinic acid synthetase: regulation of activity in various tissues of the aging rat
Arch. Biochem. Biophys
(1978) - et al.
Characterization of NO binding to human cystathionine β-synthase: possible implications of the effects of CO and NO binding to the human enzyme
J. Inorg. Biochem
(2001) - et al.
The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease
Neurobiol. Aging
(2001) - et al.
Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response
Comp. Biochem. Physiol. C
(2002) - et al.
A novel enhancing mechanism for hydrogen sulfide-producing activity of cystathionine β-synthase
J. Biol. Chem
(2002) - et al.
Homocysteine metabolism in children with Down syndrome: in vitro modulation
Am. J. Hum. Genet
(2001) - et al.
Cystathionine beta synthase: gene dosage effect in trisomy 21
Biochem. Biophys. Res. Commun
(1985)
Mental retardation in Down syndrome: a hydrogen sulfide hypothesis
Med. Hypoth
Active glycation in neurofibrillary pathology of Alzheimer's disease: Nε-(carboxymethyl) lysine and hexitol-lysine
Free Radic. Biol. Med
Early glycoxidation damage in brains from Down's syndrome
Biochem. Biophys. Res. Commun
Unusual susceptibility of heme proteins to damage by glucose during non-enzymatic glycation
Biophys. Chem
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease
N. Engl. J. Med
Hydrogen sulfide is produced in response to neuronal excitation
J. Neurosci
Cited by (52)
Rational design of dual-channel response fluorescent probe and its application for highly efficient biothiols imaging in living samples
2024, Journal of Photochemistry and Photobiology A: ChemistryTargeting Free Radicals in Oxidative Stress-Related Human Diseases
2017, Trends in Pharmacological SciencesCitation Excerpt :The role of oxidative stress in AD is documented by various animal experiments which revealed that oxidative stress markers such as lipid peroxidation precede Aβ pathology. It has been reported that homocysteine, a non-protein amino acid, is important in AD [69]; because AD patients exhibit increased concentrations of homocysteine in plasma and serum, this might be thus considered as a potential blood biomarker of AD. In addition, it has been demonstrated that a tight interaction of homocysteine with iron together with increased protein carbonylation is a prerequisite for oxidative damage to occur.
Therapeutic benefits of H<inf>2</inf>S in Alzheimer's disease
2014, Journal of Clinical NeuroscienceCitation Excerpt :It is now established that elevated plasma Hcy is a strong, independent risk factor of AD [13,14,42–44]. Therefore, Hcy is regarded as a novel therapeutic target for AD [14]. It has been shown that H2S partly prevents HHcy-associated renal damage through its antioxidant properties [45] and protects against Hcy-induced cytotoxicity and oxidative stress in vascular smooth muscle cells [46].
- 1
B.E.D. and M.A.S. developed the initial hypothesis, and thereafter all authors contributed equally to this work.